Pharmacologic approaches for the treatment of chronic insomnia

Clinical Cornerstone

Volumn 5, Issue 3, 2003, Pages 16-27

  Neubauer, David N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BROMIDE; CHLORAL HYDRATE; DIPHENHYDRAMINE; ESTAZOLAM; FLUOXETINE; FLURAZEPAM; HISTAMINE H1 RECEPTOR ANTAGONIST; HYPNOTIC AGENT; MELATONIN; METHAQUALONE; MIRTAZAPINE; PARALDEHYDE; PLACEBO; QUAZEPAM; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TRAZODONE; TRIAZOLAM; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

ALCOHOL CONSUMPTION; BEHAVIOR THERAPY; COGNITIVE THERAPY; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DELIRIUM; DEPRESSION; DIET SUPPLEMENTATION; DROWSINESS; DRUG ABUSE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEADACHE; HOMEOPATHY; HUMAN; INSOMNIA; NAUSEA; PAIN; PATIENT CARE; PATIENT EDUCATION; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOTHERAPY; RESTLESS LEGS SYNDROME; REVIEW; SEROTONIN SYNDROME; SLEEP; SLEEP APNEA SYNDROME; SLEEP WAKING CYCLE; SOMNOLENCE; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT;

EID: 0242551974     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(03)90032-9     Document Type: Article

References (25)

1. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res. 2003;27:9-15.
2. Spielman AJ, Saskin P, Thorpy MJ. Treatment of chronic insomnia by restriction of time in bed. Sleep. 1987;10:45-56.
3. Zorick FJ, Walsh JK. Evaluation and management of insomnia: An overview. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:615-623.
4. Benca RM. Mood disorders. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:1140-1157.
5. Morin CM. Insomnia: Psychological Assessment and Management. New York, NY: Guilford Press; 1993.
6. Perlis ML, Giles DE, Buysse DJ, et al. Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord. 1997;42: 209-212.
7. Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry. 1999;60: 668-676.
8. Allard S, Sainati SM, Roth-Schechter BF, MacIntyre J. Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women. Drug Metab Dispos. 1998;26:617-622.
9. Allard S, Sainati SM, Roth-Schechter BF. Co-administration of short-term zolpidem with sertra-line in healthy women. J Clin Pharmacol. 1999; 39:184-191.
10. Wehr TA. Sleep loss: A preventable cause of mania and other excited states. J Clin Psychiatry. 1989; 50(Suppl):8-16.
11. Roehrs T, Roth T. Sleep, sleepiness, sleep disorders and alcohol use and abuse. Sleep Med Rev. 2001; 5:287-297.
12. NHLBI Working Group on Insomnia. Insomnia: Assessment and Management in Primary Care. 1998; NIH Publication No. 98-4088.
13. Basu R, Dodge H, Stoehr GP, Ganguli M. Sedative-hypnotic use of diphenhydramine in a rural, older adult, community-based cohort: Effects on cognition. Am J Geriatr Psychiatry. 2003;11: 205-213.
14. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-713.
15. Mendelson WB. Hypnotics: Basic mechanisms and pharmacology. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:407-413.
16. Verster JC, Volkerts ER, Schreuder AH, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol. 2002;22:576-583.
17. Elie R, Ruther E, Farr I, et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry. 1999;60:536-544.
18. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: A post-marketing surveillance of 16,944 cases. Int Clin Psychopharmacol. 1998;13:157-167.
19. Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy. JAMA. 1997;278:2170-2177.
20. Scharf MB, Roth T, Vogel GW, Walsh JK. A multi-center, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55:192-199.
21. Walsh JK, Vogel GW, Scharf M, et al. A five-week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med. 2000;1:41-49.
22. Darcourt G, Pringuey D, Salliere D, Lavoisy J. The safety and tolerability of zolpidem - an update. J Psychopharmacol. 1999;13:81-93.
23. Friedmann PD, Herman DS, Freedman S, et al. Treatment of sleep disturbance in alcohol recovery: A national survey of addiction medicine physicians. J Addict Dis. 2003;22:91-103.
24. Walsh JK, Roth T, Randazzo A, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep. 2000;23:1087-1096.
25. Walsh JK. Zolpidem "as needed" for the treatment of primary insomnia: A double-blind, placebo-controlled study. Sleep Med Rev. 2002;6(Suppl 1): S7-S10.